Piper Jaffray Downgrades Endocyte (ECYT) to Neutral
Tweet
Share
E-mailGet Alerts ECYT Hot Sheet
Price: $23.99 --0%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 6 | New: 18
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 6 | New: 18
Join SI Premium – FREE
Piper Jaffray downgraded Endocyte (NASDAQ: ECYT) from Overweight to Neutral with a price target of $13.50.
For an analyst ratings summary and ratings history on Endocyte click here. For more ratings news on Endocyte click here.
Shares of Endocyte closed at $17.38 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Downgrades Procept BioRobotics Corp (PRCT) to Hold
- Barclays Downgrades Dana Holding (DAN) to Equalweight
- ICICI Securities Downgrades Tech Mahindra Ltd. (TECHM:IN) to Reduce (4)
Create E-mail Alert Related Categories
DowngradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
